Silexion Therapeutics Corp received a delisting notice from Nasdaq on August 18, 2026, for failing to maintain the minimum $2.5 million shareholders' equity requirement under Listing Rule 5550(b)(1). The company reported shareholders’ equity of only $44,000 as of June 30, 2026, and does not meet alternative continued listing standards. Silexion intends to appeal the determination before a Nasdaq Hearings Panel by August 25, 2026. The company is subject to a Mandatory Hearings Panel Monitor following a September 23, 2025 decision, which prevents Nasdaq from granting additional time for compliance during the one-year monitoring period. If the appeal fails, trading in ordinary shares and warrants would be suspended and removed from Nasdaq listing. Silexion Therapeutics Corp operates as a clinical-stage biopharmaceutical company focused on developing novel therapies.

Silexion Therapeutics Corp filed a Current Report on Form 8-K to announce the retroactive adjustment of its audited financial statements for the year ended December 31, 2025, and unaudited interim financial statements for the quarter ended March 31, 2026. These adjustments reflect a 1-for-10 reverse share split that was effected on May 28, 2026, following shareholder approval at an extraordinary general meeting held in April and May 2026. The adjusted financial statements are attached as Exhibit 99.1 and incorporated by reference into the filing. Silexion Therapeutics Corp operates in the biotechnology industry, developing RNA interference therapies for KRAS-driven cancers.

Silexion Therapeutics Corp consummated a public offering on August 13, 2026, raising approximately $2.5 million in gross proceeds by selling ordinary shares and pre-funded warrants at $0.65 per unit. The company also converted $750,001 of principal from its Sponsor Note into 1,153,848 ordinary shares at the offering price, reducing the note balance to $206,462. Net proceeds were estimated at $2.1 million after deducting placement agent fees and expenses. The company intends to use the capital to advance its SIL204 clinical trial for locally advanced pancreatic cancer and for general corporate purposes. Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers.

Professor Amnon Peled resigned from the Board of Silexion Therapeutics Corp on July 30, 2026, effective August 1, 2026. The resignation was for personal reasons and did not result from any disagreement with the Company regarding its operations, policies, or practices. This company operates in the biotechnology industry.

On July 20, 2026, Silexion Therapeutics Corp shareholders approved two proposals at a reconvened extraordinary general meeting. First, the company increased its authorized share capital by 10,000,000 ordinary shares, raising the total from 5,900,000 to 15,900,000 shares with a par value of $0.135 each. Second, shareholders approved the exercisability of 399,020 Series C and D ordinary warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share, both stemming from a May 18, 2026 transaction. The memorandum amendment became effective on July 21, 2026. Silexion Therapeutics Corp is a biotechnology company that develops therapeutic treatments.